Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

Last week
Deals
China

Biden's fight with Mod­er­na over pro­vid­ing vac­cines for the poor­est coun­tries in­ten­si­fies

Last week
Coronavirus

Spurned by the FDA, Arde­lyx ex­ecs grab bonus­es to stay on while ax­ing near­ly two-thirds of re­main­ing staff

Last week
People
Pharma

Eli Lil­ly bags FDA nod for Verzenio in ear­ly breast can­cer, but a con­tro­ver­sial di­ag­nos­tic could dog its roll­out

Last week
Pharma
FDA+

Drawn to the idea of turn­ing B cells in­to 'pro­tein fac­to­ries,' Take­da jumps in­to a mile­stone-heavy, $900M pact

Last week
Deals
Cell/Gene Tx

In­tel­lia en­ters Ed­i­tas’ turf with oc­u­lar CRISPR pact

Last week
Deals
Cell/Gene Tx

CRISPR Ther­a­peu­tics claims safe­ty ad­van­tage in first big look at off-the-shelf CAR-T da­ta, but dura­bil­i­ty in ques­tion

Last week
R&D
Cell/Gene Tx

FDA still is­n't re­al­ly throw­ing its weight be­hind Covid-19 vac­cine boost­ers, Mod­er­na's ad­comm brief­ing docs show

Last week
Coronavirus

In­side the deal: As leaked de­tails goosed its stock, Ac­celeron's CEO pumped Mer­ck for more cash

Last week
Deals

J&J sci­ence lead Paul Stof­fels set to re­tire amid brain trust shake­up at world's largest drug­mak­er

Last week
People

Sci­en­tist be­hind Mer­ck­'s Covid pill: We need to watch out for re­sis­tance

Last week
R&D
Coronavirus

Post-split GSK to ex­it mar­quee world HQ, blue­print­ing small­er cor­po­rate digs

Last week
Pharma

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

Last week
R&D

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

Last week
R&D

Search­ing for the next 'big hairy goal,' Blue­Rock CEO Emile Nuwaysir jumps to in vi­vo cell ther­a­py start­up En­so­ma

Last week
People
Cell/Gene Tx

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; Chart­ing biotech's Q3; and more

Last week
Weekly

The FDA adds a failed Alzheimer's drug to the 'break­through' club now look­ing for a near-term OK

Last week
FDA+

Re­lay un­rolls ear­ly da­ta for an­ti-FGFR drug it thinks stand alone in terms of safe­ty pro­file

Last week
R&D

New­ly re­vealed texts from ex-FDA leader Stephen Hahn of­fer be­hind-the-scene glimpse in­to Trump’s Covid scare

Last week
FDA+

UP­DAT­ED: An­oth­er three biotechs are set to de­but on Nas­daq as com­bined in­dus­try raise tops $14B

Last week
Financing

Al­lo­gene hit with FDA clin­i­cal hold af­ter a pa­tient ex­pe­ri­ences 'ab­nor­mal­i­ty' in CAR-T cells — shares ham­mered

2 weeks ago
R&D
FDA+

New Eng­land-based dis­trib­u­tor HP­NE looks to dou­ble its work­force to keep up with de­mand

2 weeks ago
Outsourcing
Manufacturing

Bay­er drops $460M in­to con­tra­cep­tive man­u­fac­tur­ing sites with the Unit­ed Na­tion­s' back­ing

2 weeks ago
Manufacturing

Biden's choice for FDA may be a wild card as top can­di­date says she's not in the run­ning

2 weeks ago
FDA+
First page Previous page 12345 Next page Last page